CPTR and the WHO Global TB Programme have partnered to help maximize the knowledge and understanding gained from completed Phase III TB drug clinical trials. The partnership will bring together an expert steering committee to analyze three contemporary Phase III trials (REMox TB, Rifaquin, and OFLOTUB). The collaboration will improve the drug development community’s understanding of important Phase III trials of fluoroquinolone-containing shortened regimens for drug-susceptible TB.
Through this collaboration, quantitative analyses will be performed to develop tools to optimize the design of future TB trial design. Among the areas to be studied is the application of markers of treatment outcomes to inform regimen selection and study design for Phase III clinical trials.